AU2017217940B2 - Cancer therapy - Google Patents

Cancer therapy Download PDF

Info

Publication number
AU2017217940B2
AU2017217940B2 AU2017217940A AU2017217940A AU2017217940B2 AU 2017217940 B2 AU2017217940 B2 AU 2017217940B2 AU 2017217940 A AU2017217940 A AU 2017217940A AU 2017217940 A AU2017217940 A AU 2017217940A AU 2017217940 B2 AU2017217940 B2 AU 2017217940B2
Authority
AU
Australia
Prior art keywords
cells
subject
days
inhibitor
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017217940A
Other languages
English (en)
Other versions
AU2017217940A1 (en
Inventor
Richard LESNIEWSKI
Doug MCNEEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madison Vaccines Inc
Original Assignee
Madison Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madison Vaccines Inc filed Critical Madison Vaccines Inc
Publication of AU2017217940A1 publication Critical patent/AU2017217940A1/en
Application granted granted Critical
Publication of AU2017217940B2 publication Critical patent/AU2017217940B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
AU2017217940A 2016-02-12 2017-02-10 Cancer therapy Expired - Fee Related AU2017217940B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US62/294,349 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US62/404,252 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Publications (2)

Publication Number Publication Date
AU2017217940A1 AU2017217940A1 (en) 2018-08-23
AU2017217940B2 true AU2017217940B2 (en) 2024-03-21

Family

ID=59088211

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017217940A Expired - Fee Related AU2017217940B2 (en) 2016-02-12 2017-02-10 Cancer therapy

Country Status (8)

Country Link
US (5) US11000578B2 (enExample)
EP (1) EP3413927A4 (enExample)
JP (2) JP2019512020A (enExample)
CN (1) CN108883203A (enExample)
AU (1) AU2017217940B2 (enExample)
CA (1) CA3013930C (enExample)
HK (1) HK1258319A1 (enExample)
WO (1) WO2017139628A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN112638947B (zh) * 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
WO2020097209A1 (en) * 2018-11-06 2020-05-14 Wisconsin Alumni Research Foundation Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220133873A1 (en) * 2019-02-08 2022-05-05 Madison Vaccines Inc. Cancer therapy
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
WO2021108331A1 (en) * 2019-11-26 2021-06-03 The Regents Of The University Of California Combination therapy for head and neck cancer
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2025500494A (ja) 2021-12-23 2025-01-09 ユニフェルシテイト マーストリヒト 免疫防護型の植込み可能な細胞送達デバイス

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7179797B2 (en) * 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
WO2011130742A2 (en) 2010-04-16 2011-10-20 Wisconsin Alumni Research Foundation Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
US8603485B2 (en) 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
PL2844282T3 (pl) * 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2016011357A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
JP2017535599A (ja) 2014-11-07 2017-11-30 ウィスコンシン アラムニ リサーチ ファンデーション Ｂ細胞標的ｄｎａワクチン
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017139755A1 (en) * 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
‘Vaccine therapy and pembrolizumab in treating patients with hormone-resistant, metastatic prostate cancer’. ClinicalTrials.gov, study: NCT02499835. Submitted date July 29, 2015 (v2). *
B. T. REKOSKE ET AL: "PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 8, 3 June 2015, pages 946 - 955 *
MCNEEL D G ET AL: "Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer", CLINICAL CANCER RESEARCH, 2014, 20(14): 3692-3704 *
REKOSKE ET AL."Abstract CN04-03: DNA vaccines as treatment for prostate cancer - understanding mechanisms of resistance. Mol Cancer Ther.", 5 Nov 2015, Retrieved from<URL:http://mct.aacrjournals.org/content/14/12_Supplement_2/CN04-03> *

Also Published As

Publication number Publication date
US20170182139A1 (en) 2017-06-29
US20190030150A1 (en) 2019-01-31
US20250074987A1 (en) 2025-03-06
US20240115684A1 (en) 2024-04-11
EP3413927A4 (en) 2019-11-27
US11000578B2 (en) 2021-05-11
CA3013930C (en) 2025-03-18
CN108883203A (zh) 2018-11-23
JP2019512020A (ja) 2019-05-09
US20210283232A1 (en) 2021-09-16
US11806391B2 (en) 2023-11-07
AU2017217940A1 (en) 2018-08-23
CA3013930A1 (en) 2017-08-17
WO2017139628A1 (en) 2017-08-17
HK1258319A1 (zh) 2019-11-08
JP2022088665A (ja) 2022-06-14
EP3413927A1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
US11806391B2 (en) Combinatorial method of treating prostate cancer
US11439697B2 (en) Nant cancer vaccine
AU2017278207B2 (en) Combination therapy consisting of ADT and an androgen receptor vaccine
Brignone et al. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study
US20220211832A1 (en) Treatment methods
WO2017139755A1 (en) Cancer therapy
Lin et al. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
US20240047009A1 (en) Nant cancer vaccine strategies
Knutson et al. A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
US20220133873A1 (en) Cancer therapy
US20230034802A1 (en) Nant Cancer Vaccine
KR20250099713A (ko) 항-pd-1 또는 항-pd-l1 항체를 이용한 암 치료
Chatta et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee